Overview
Status
Active
Registry date
2015-12-03
Share capital
5,000.00 PLN
Registered address
ul. Piotrkowska 25, 80-001 Gdańsk, Poland
Electronic delivery address
AE:PL-47160-89294-GRDJE-19
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 40 days late).
- 202501/06/2026
- 202410/07/2025
- 202305/07/2024
- 202226/06/2023
- 202124/08/2022
- 202014/05/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 1.46mMedianUSD 1.92mAverageUSD 5.20m
Net profit
This companyUSD 59.66kMedianUSD 20.66kAverageUSD 86.55k
Operating costs
This companyUSD 1.38mMedianUSD 1.88mAverageUSD 5.04m
Assets
This companyUSD 669.41kMedianUSD 544.32kAverageUSD 1.76m
Industry
National Health Fund (NFZ) contracts
LUX Pharm has been an NFZ healthcare provider since 2024. In 2026 it is performing 2 contracts with a total value of USD 162.07. All its contracts were worth USD 337.86 in total.
NFZ contract value by year (USD)
| Type of care | NFZ branch | Contracts | Value in 2026 |
|---|---|---|---|
| Pilot programmes | pomorskie | 1 | USD 162.07 |
| Other services provided in pharmacies | pomorskie | 1 | USD 0.00 |
Authorized Representatives
Adam Marcin Pecyna – President of the Management Board
Tomasz Płonka – Attorney-in-fact (sole)
Manner of representation
Each member of the management board is independently authorised to make declarations of will on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Artur Dawid Cyzioage 51 | 13 | $351.16 | 26% |
| 37 | $999.46 | 74% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2015-11-27.
04 1050 1953 1000 0090 3089 2450
89 1140 1049 0000 3693 3100 1001
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 29, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $24,099$24,099 | Polski Fundusz Rozwoju S.A. |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Farmjugsp. z o.o. | $14,506,326.49 | farmjug.pl | ||
| Farmjug Agsp. z o.o. | $4,213,734.86 | farmjug.pl | ||
| Vitasp. z o.o. | $1,873,952.10 | vita-wroclaw.pl | ||
| Gold Lionsp. z o.o. | $1,669,649.21 | goldlion.pl | ||
| Grupa Aptekarska Kujałowiczsp. j. | $1,452,484.91 | wga.pl | ||
| Herbarium Świętego Franciszkasp. z o.o. | $1,397,577.12 | herbarium.katowice.pl | ||
| Eurekasp. z o.o. | $1,377,733.77 | fundacja-eureka.edu.pl | ||
| MaglowS.A. | $1,356,219.12 | maglow.pl | ||
| Farmacja Im. O. Klimuszkisp. z o.o. | $1,289,548.20 | zyj-zdrowo.com | ||
| Twoja Tania Apteka Farmarsp. z o.o. | $440,843.57 | domlekow.pl |
Change history
| Date | Event | |
|---|---|---|
| 2020-01-27 | Address change (Ul. Odkryta 51b/4, 03-140, Warszawa → Ul. Piotrkowska 25, 80-001, Gdańsk) | |
| 2015-12-03 | Entered in the register |
FAQ
The main business activity of LUX Pharm focuses on dispensing chemist in specialised stores.
The company was registered in the Polish National Court Register (KRS) on December 3, 2015.
The headquarters is located at: ul. Piotrkowska 25, 80-001 Gdańsk.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company generated total revenue of $1,457,350, representing an increase of 12.1% compared to 2024.
Yes, in 2025 the company was profitable, achieving a net profit of $59,664, meaning the company increased its profit by 20.0%.
The largest operating cost category falls under other operating costs. This category amounted to $1,118,435 in 2025, representing 81% of all operating expenses.
Last updated: 2026-06-02